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Background: Berberine (BBR), a component from traditional Chinese medicine, has been shown to possess
anti-tumor activity against a wide spectrum of cancer cells including human lung cancer, but the detailed
mechanism underlining this has not been well elucidated.
Methods: In this study, the effect of berberine on cell growth and apoptosis were assessed by MTT, flow cytometry
and Hoechst 33258 staining assays. The phosphorylation of p38 MAPK and ERK1/2, and expressions of p38 MAPK
isoforms α and β, total ERK1/2, p53, FOXO3a and p21 protein were evaluated by Western Blot analysis. Silencing of
p38 MAPK isoform α and β, p53, FOXO3a and p21 were performed by siRNA methods. Exogenous expression of
FOXO3a was carried out by electroporated transfection assays.
Results: We showed that BBR significantly inhibited growth and induced cell cycle arrest of non small cell lung
cancer (NSCLC) cells in the G0/G1 phase in a dose-dependent manner. Furthermore, we found that BBR increased
phosphorylation of p38 MAPK and ERK1/2 in a time-dependent and induced protein expression of tumor
suppressor p53 and transcription factor FOXO3a in a dose-dependent fashion. The specific inhibitor of p38 MAPK
(SB203580), and silencing of p38α MAPK by small interfering RNAs (siRNAs), but not ERK1/2 inhibitor (PD98059)
blocked the stimulatory effects of BBR on protein expression of p53 and FOXO3a. Interestingly, inhibition of p53
using one specific inhibitor (Pifithrin-α) and silencing of p53 using siRNAs overcome the inhibitory effect of BBR on
cell growth. Silencing of FOXO3a appeared to attenuate the effect of BBR on p53 expression, cell proliferation and
apoptosis. Furthermore, BBR induces the protein expression of cell cycle inhibitor p21 (CIP1/WAF1), which was not
observed in cells silencing of p53 or FOXO3α gene. Intriguingly, exogenous expression of FOXO3a enhanced the
expression of p21 (CIP1/WAF1) and strengthened BBR-induced apoptosis.
Conclusion: Our results show that BBR inhibits proliferation and induces apoptosis of NSCLC cells through
activation of p38α MAPK signaling pathway, followed by induction of the protein expression of p53 and FOXO3a.
The latter contribute to the BBR-increased p21 (CIP1/WAF1) protein expression. The exogenous FOXO3a, interaction
and mutually exclusive events of p53 and FOXO3a augment the overall response of BBR.
Keywords: Berberine, Human lung cancer cells, p38α MAPK, p53, FOXO3a, p21* Correspondence: swhan2010@live.com
1Laboratory of Tumor Molecular Biology and Targeted Therapies of Chinese
Medicine, 4th Floor, Scientific Research Building, Neihuan West Road No. 55,
University City, Panyu District, Guangzhou, Guangdong Province, P. R. China,
510006
Full list of author information is available at the end of the article
© 2014 Zheng et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Zheng et al. Journal of Experimental & Clinical Cancer Research 2014, 33:36 Page 2 of 12
http://www.jeccr.com/content/33/1/36Introduction
Lung cancer is the leading cause of cancer death world-
wide with poor 5-year survival rate [1,2]. Current treat-
ments for patients with advanced lung cancer result in
rarely curative, and the relapse often occur, which high-
lights the large need development of novel therapeutic
agents against this type of malignancy. Traditional Chinese
Medicine (TCM) plays an important role in protecting
cancer patients against suffering from complications,
assisting in supportive and palliative care by reducing
side-effects of conventional treatment and improving
quality of life [3] However, the molecular mechanisms
by which there herbs in enhancing the therapeutic
efficiency against the lung malignancies remain poorly
understood.
Berberine (BBR) is a benzylisoquinoline alkaloid ex-
tracted from many kinds of medicinal plants that has
been extensively used as a TCM and exhibits a wide
spectrum of pharmacological activities [4]. Recently,
BBR has been reported to have anti-tumor effects on
many types of cancer cells [5], and present studies sup-
plied evidence that BBR can inhibit proliferation of non
small cell lung cancer (NSCLC) cells, and have no cyto-
toxic effects on normal human bronchial epithelial cells
[6]. However, the detailed mechanism of its anti-cancer
activity has not been well elucidated.
The tumor suppressor p53, a sequence-specific tran-
scription factor that activates the expression of genes in-
volved in apoptosis, cell cycle arrest and senescence, has
a wide range of functions covering cell cycle control,
apoptosis, genome integrity maintenance, metabolism,
fertility, cellular reprogramming and autophagy [7-10].
Although different underlying mechanisms for p53 regu-
lation have been proposed for decades, none of them is
conclusive. Forkhead homeobox type O3a (FOXO3a,
FKHRL1) is also a transcription factor with known
tumor suppressor activity and belongs to the family of
mammalian forkhead transcription factors, which are
regulated by growth factor receptor-induced activation
of the phosphatidylinositol 3-kinase (PI3-K)/Akt (or pro-
tein kinase B) signaling pathway [11]. Studies in mam-
malian cells have shown that activation of FOXO3a
stimulated the expression of proteins that are involved
in apoptosis [11] and cell cycle arrest [12] in different
types of cells. FOXO3a was implicated with tumor sup-
pression and inhibition of FOXO3a expression promoted
cell transformation, tumor progression and angiogenesis
[13]. The cyclin-dependent kinase inhibitors p21 (CIP1/
WAF1) has been shown to be involved in the cell cycle
control, DNA replication, cell differentiation and apop-
tosis [14]. Studies demonstrated the link of p53, FOXO3a
and p21 signaling in control of cancer cell growth
[15-17]. However, the detailed mechanism by these in-
teractions is still inconclusive.In this report, we show that BBR inhibits growth and in-
duces apoptosis of lung adenocarcinoma cells through acti-
vation of p38 mitogen activated protein kinase alpha (p38α
MAPK). This, in turn, leads to increase the expressions
and protein interactions of p53 and FOXO3a, followed by
the induction of cell cycle inhibitor p21 (CIP1/WAF1).
Materials and methods
Reagents
Monoclonal antibodies specific for cyclinD1, p38 MAPK iso-
forms α, extracellular signal-regulated kinase 1/2 (ERK1/2)
and their phosphor-forms were purchased from Cell Signal-
ing Technology (Beverly, MA, USA). p38 MAPK isoforms β
was ordered from AVIVA System Biology (San Diego, CA,
USA). The cyclin D1, p21, p53, FOXO3a and phosphor-
form p53 antibodies were abstained from Epitomics (Burlin-
game, CA, USA). PD98059 (a special inhibitor of ERK1/2),
SB203580 (a special inhibitor of p38 MAPK) were purchased
from Merck Millipore (Darmstadt, Germany), MTT powder
and Pifithrin-α (PFT-α) were purchased from Sigma Aldrich
(St. Louis, MO, USA). p38 MAPK isoforms α and β, p53
and FOXO3a small interfering RNAs (siRNAs) were obtained
from Santa Cruz (California, CA, USA). Lipofectamine 2000
reagent was purchased from Invitrogen (Carlsbad, CA, USA).
The FOXO3a-GFP and N1-GFP plasmids were kindly pro-
vided by Dr. Frank M. J. Jacobs (Rudolf Magnus Institute
of Neuroscience, University Medical Center, Utrecht, the
Netherland) and was reported previously [18]. Berberine was
purchased from Chengdu Must Biotechnology (Chengdu,
China).
Cell culture
The NSCLC cell lines (A549, PC9, H1650 and H1299)
were obtained from the Chinese Academy of Sciences
Cell Bank of Type Culture Collection (Beijing, China)
and the Cell Line Bank at the Laboratory Animal Center of
Sun Yat-sen University starting March 2012 (Guangzhou,
China) and grown in RPMI-1640 medium supplemented
with 10% heat-inactivated FBS, HEPES buffer, 50 IU/mL
penicillin/streptomycin, and 1 μg amphotericin (complete
medium). All cell lines have been tested and authenti-
cated for absence of Mycoplasma, genotypes, drug re-
sponse, and morphology using a commercial available
kit (Invitrogen, Shanghai, China) in the Laboratory and
in the Animal Center at Sun Yat-sen University. The
BBR was dissolved in a small amount of dimethylsulfoxide
[DMSO, maximum concentration, 0.1% (v/v)], which was
then added to complete cell culture medium prior to
addition to sub confluent cells. Cells treated with vehicle
only (DMSO, 0.1% in media) was served as control.
Cell viability assay
NSCLC cells were seeded in 96-well plates at 5 × 103
cells/well, and incubated at 37°C in complete medium
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with SB203580, PD98059, or pifithrin-α for 2 h or were
transfected with control, or p53 and FOXO3a siRNAs
for 24 h before exposure of the cells to BBR for an add-
itional 24 h. Afterwards, cell viability were measured using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay according to the instruction from the
provider.
Cell cycle analysis
NSCLC cells were cultured in 6-well plates at 2 × 105
cells/well and treated with increased doses of BBR for 24
h or with SB203580, PD98059, or pifithrin-α for 2 h,
followed by BBR for an additional 24 h. Afterwards, the
cells were harvested, washed twice with phosphate-
buffered saline (PBS), and resuspended in 500 μL of cold
PBS and ethanol (1.5 mL) for 2 h at 4°C. The fixed cells
were incubated in 1 mL of 0.1% sodium citrate contain-
ing propidium iodide (PI) 0.05 mg and 50 μg RNase for
30 min at room temperature (RT) in the dark. The cell
cycle analysis was detected by flow cytometry (FC500,
Beckman Coulter, FL, USA), and the proportion (per-
centage) of cells within the G1, S, and G2/M phases of
the cell cycle were analyzed using the MultiCycle AV
DNA Analysis software (Phoenix Flow Systems).
Western blot analysis
NSCLC cells were harvested, washed and lysed with 1 ×
RAPI buffer. Protein concentrations were determined by
the Thermo BCA protein assay Kit. Equal amounts of pro-
tein from cell lysates were separated on 10% and 12% SDS
polyacrylamide gels, and transferred onto polyvinylidene
fluoride membranes. Membranes were blocked with 5%
non-fat milk in TBST and incubated with primary anti-
bodies against p38 MAPK (including p38 α and β isoforms),
ERK1/2 and their phosphor-forms, FOXO3a, p53, p21 and
cyclinD1 at 4°C overnight. Afterwards, the membranes were
washed and incubated with a secondary antibody against
rabbit or mouse IgG conjugated to horseradish peroxidase
(Cell Signaling, MA, USA) for 1 h, followed by washing and
transferring into ECL solution (Millipore, Darmstadt,
Germany), and exposed to X-ray film.
Treatment with p38 isoforms, p53 and FOXO3a small
interfering RNAs (siRNAs)
For the transfection procedure, cells were seeded in 6-
well or 96-well culture plates in RPMI 1640 medium
containing 10% FBS (no antibodies), grown to 60% con-
fluence, and p38 MAPK isoforms α, β, p53, FOXO3a
and control siRNAs were transfected using the lipofecta-
mine 2000 reagent according to the manufacturer’s in-
structions. Briefly, Lipofectamine 2000 was incubated
with Opti-MEM medium (Invitrogen, CA, USA) for
5 min, mixed with siRNA (up to 70 nM), and incubatedfor 20 min at RT before the mixture was added to cells.
After culturing for up to 30 h, the cells were washed and
resuspended in fresh media in the presence or absence
of BBR for an additional 24 h for all other experiments.
Cell apoptosis assays
Cell apoptosis was analyzed with Annexin V-FITC/PI
Apoptosis Detection Kit (BestBio, Shanghai, China) ac-
cording to instructions from the manufacturer. Briefly,
after treated with BBR for 24 h, the apoptotic cells were
harvested by Trypsin (no EDTA) and washed with PBS,
then resuspended the cells in 500 μL binding buffer,
5 μL Annexin V-FITC regent and 10 μL PI regents and
incubated for 5 min at RT in the dark, followed by de-
tecting cell apoptosis by flow cytometry.
In parallel experiment, Hoechst 33258 staining was used
to further analyze cell apoptosis. Cells were cultured in
12-well culture plates and treated with berberine for 24 h.
Afterwards, the cells were washed with PBS, and incu-
bated with 500 μL 4% methanal for 10 min, followed by
staining with Hoechst 33258 (Sigma, St. Louis, MO, USA)
at RT for 10 min, then observed with filters for blue fluor-
escence under fluorescence microscopy.
Electroporated transfection assays
NSCLC cells (1 × 107 cells/mL) were washed and centri-
fuged at 1200 rpm for 5 min, followed by removing the
medium and PBS. Afterwards, the cells in the tubes were
added Bio-Rad Gene Pulser electroporation buffer. After
resuspending the cells, the desired N1-GFP or FoxO3a-
GFP plasmid DNA (10 μg/mL) were added and the elec-
troporation plate were put in the MXcell plate chamber
and closed the lid in Gene Pulser II Electroporation System
(Bio-Rad, CA, USA). The electroporation conditions on
the plates to deliver 150 V/5 ms square wave were adjusted
until reaching the optimal one. Once the condition has
been set and then press “Pulse” to electroporate the cells.
After electroporation was completed, the cells were trans-
ferred to a tissue culture plate. We typically transfer each
150 μL electroporation sample into a 6-well culture plate
containing 2 mL RPMI1640. Cells were incubated for 48 h
at 37°C, then treated with BBR for an additional 24 h.
Statistical analysis
All data were expressed as mean ± SD of three independ-
ent experiments, and analyzed by one-way ANOVA
followed by post hoc testing or two-way ANOVA followed
by Tukey’s Multiple Comparison Test for multiple com-
parison involved. These analyses were performed using
GraphPad Prism software version 5.0 (GraphPad Software,
CA, USA). Asterisks showed in the figures indicate signifi-
cant differences of experimental groups in comparison
with the corresponding control condition. P-values <0.05
were considered statistically significant.
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BBR inhibited human lung carcinoma cell growth and caused
G0/G1 arrest in a dose- and time-dependent manner
We first detected the effect of BBR on cell growth in human
NSCLC cells A549 by MTT assay. As show in Figure 1A
and B, BBR decreased the cell viability in a dose- and time-
dependent manner with maximal dose of 50 μM at 48 h
treatment. Similar results were also observed in other
NSCLC cell lines (Figure 1C). To further examine the effects
of BBR on cell proliferation, cell cycle phase distribution of
NSCLC cells treated with increased doses of BBR for 24 h
was analyzed by Flow cytometry after propidium iodide
staining. We showed that, compared with the untreated
control cells, BBR significant increased the proportion of
cells at G0/G1 phase, while the proportion of cells at S
phases were reduced (Figure 1D) suggesting that BBR in-
duced cell cycle arrest in G0/G1 phase in A549 cells.
BBR induced apoptosis in NSCLC cells
We also examine the effect of BBR on apoptosis in NSCLC
cells. We found that A549 cells treated with increased con-
centrations of BBR for 24 h resulted in induction of apop-
tosis shown in the lower right (AB4) quadrants of the
histograms, which were counted as “early” apoptotic cells
(Figure 2A) as detected using the Annexin V-FITC/PI stain
Apoptotic Detection Kit. After 24 h of treatment, the BBR-
induced apoptotic rate was greater than that in the non-
treated control cells (Figure 2A). Similar results were ob-
tained in an additional NSCLC cell line PC9 cells (not
shown). Meanwhile, the effect of BBA on apoptosis of
A549 cells were also tested using Hoechst 33258 staining
under fluorescence microscopy. We observed the apoptotic
morphologic changes as compared to the control group.
The BBR-treated cells showed marked granular apoptotic
bodies (Figure 2B). Together, the results above suggested
that BBR induced apoptosis in NSCLC cells.
BBR increased the phosphorylation of p38 MAPK and
ERK1/2 in a time-dependent fashion
ERK1/2 and p38 MAPK signaling pathways were involved
in apoptosis and cell growth depending on the cell type
and stimuli. We showed that BBR increased the phosphor-
ylation of ERK1/2 and p38 MAPK in a time-dependent
fashion (Figure 3A-B). Note that the expression of total
ERK1/2 and p38 MAPK proteins had no significant
changes after BBR treatment. Similar results were obtained
in an additional NSCLC cell line PC9 cells (not shown).
BBR increased protein levels of p53 and FOXO3a through
p38 MAPK pathway
It has reported that p53 cooperated with BBR-induced
growth inhibition and apoptosis of NSCLC cells [6]. In this
study, we showed that BBR increased FOXO3a, a transcrip-
tion factor with known tumor suppressor activity [11],protein expression in a dose-dependent manner (Figure 4A).
Similar results were obtained with PC9 cells (not shown).
Next, we used special inhibitors of p38 MAPK and ERK1/2
to pre-treated A549 cells to examine the role of these ki-
nases in mediating the effect of BBR on induction of p53
and FOXO3a. As shown in Figure 4B, we found that the
inhibitor of p38 MAPK (SB203580) abrogated BBR-
induced p53 and FOXO3a protein expression, while
the inhibitors of ERK1/2 (PD98059) had no effect
(Figure 4D). Similar results were observed using p38
MAPK siRNAs; intriguingly, we found that silencing of
p38α (Figure 4C), but not p38β isoforms (not shown),
abrogated the effect of BBR on p53 or FOXO3a protein
expression. This result suggested that activation of p38α
isoform was involved in the BBR-induced p53 and
FOXO3a protein expression; and that activation of
ERK1/2 played no role in this process.
Previously, we showed that BBR induced cell cycle ar-
rest in G0/G1 phase. To further examine the role of p38
MAPK activation in this process, we first treated cells
with p38 and ERK inhibitors before exposing the cells to
BBR. As shown in Figure 4E-F, compared with BBR
treated alone, SB203580 blocked the BBR-caused a de-
crease in the proportion of cells at S phases (E), and cell
proliferation (F). This indicated the role of p38 MAPK
activation in mediating the effect of BBR on cell cycle ar-
rest. Note that PD98059 had no effect (not shown).
BBR-induced inhibition of cell growth and induction of
apoptosis were dependent on p53 and FOXO3a protein
expression, respectively
Studies have shown that p53 and FOXO3a regulated cell
growth and apoptosis processes. In this study, we found
that p53 special inhibitor pifithrin-α showed to overcome
the effect of BBR on cell proliferation and G0/G1 arrest
(Figure 5A and B). Note that p53 special inhibitor
pifithrin-α blocked the effect of BBR on p53 protein ex-
pression (Figure 5A upper panel) and induced G2/M phase
(Figure 5B). As expected, silencing of p53 by siRNA signifi-
cantly reversed the BBR-inhibited cell growth (Figure 5C).
While silencing of p53 reduced the p53 protein expression
(Figure 5C, upper panel), it had no effect on BBR-induced
FOXO3a (Figure 5C). On the other hand, silencing of
FOXO3a partially reversed the BBR-induced p53 protein
expression and cell proliferation (Figure 5D). Furthermore,
it attenuated in part the BBR-induced apoptosis as deter-
mined by flow cytometry assays (Figure 5E). On the con-
trary, exogenous expression of FOXO3a enhanced the
effect of BBR on apoptosis (Figure 5F). The above findings
suggested that induction and potential cross talk of p53
and FOXO3a contributed to the BBR-inhibited cell growth
and -induced apoptosis. This also implied that the inhib-
ition of proliferation could by in part a consequence of
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Figure 1 Berberine (BBR) inhibited human lung carcinoma cell growth and caused G0/G1 arrest in a dose- and time-dependent
manner. A, A549 cells were treated with increased concentrations of BBR for 48 h to examine the cell viability. B, A549 cells were treated with
BBR (50 μM) for the indicated time to examine the cell viability. C, NSCLC cell lines indicated were treated with BBR (50 μM) for 48 h. The cell
viability was determined using the MTT assay as described in the Materials and Methods Section and was expressed as percentage of control in
the mean ± SD of three separate experiments. *indicates significant difference as compared to the untreated control group (P < 0.05). D, A549
cells were treated with increased doses of BBR for 24 h. Afterwards, the cells were collected and processed for analysis of cell cycle distribution
by flow cytometry after propidium iodide (PI) staining. And the percentages of the cell population in each phase (G0/G1, S and G2/M) of cell
cycle were assessed by Multicycle AV DNA Analysis Software. Data are expressed as a percentage of total cells. Values are given as the mean ± SD
from 3 independent experiments performed in triplicate. *indicates significant difference as compared to the untreated control group (P < 0.05).
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and FOXO3a in lung cancer cells
In order to further explore the mechanism by which
BBR control cell growth, we tested the cell cycle related
protein expression affected by BBR. We found that BBR
induced p21 and decreased cyclin D1 expression in a
dose-dependent manner with maximal effect at 25 μM
(Figure 6A-B). Moreover, we also observed that silencingof p53 or FOXO3a abolished the effect of BBR on p21
(Figure 6C-D) but not cyclin D1 (not shown) protein
expression. In addition, the effect of BBR on p21 protein
expression was potentiated by overexpression of
FOXO3a (Figure 6E). These results indicated that ex-
pression of p53 and FOXO3a were required in mediating
the effect of BBR on induction of p21 protein expression
in lung cancer cells.
Figure 2 Berberine induced apoptosis in lung cancer cells. A, A549 cells were treated with increased concentrations of BBR for 24 h.
Afterwards, cells were harvested for analysis of apoptosis using the Annexin V-FITC/PI Apoptosis Detection Kit as detailed in Materials and
Methods Section. The AB3 quardrant (annexin V-/PI-), AB4 quadrant (annexin V+/PI-) and AB2 quadrant (annexin V+/PI+) of the histograms
indicated the percentage of normal cells, early apoptosis and late apoptosis, respectively. Data are expressed as a percentage of total cells. Values
in bar graphs were given as the mean ± SD from three independent experiments performed in triplicate. *indicates significant difference as
compared to the untreated control group (P < 0.05). B, Apoptotic nuclear morphology changes induced by BBR treatment for 48 h were observed
by Hoechst 33258 staining in A549 cells. Panel showed Hoechst 33258 nuclear staining. Arrows indicate chromatin condensation and nuclear
fragmentation (×100 magnification). Fluorescence images were taken after Hochest 33258 staining.
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Berberine (BBR), a promising phytochemical drug and
isoquinoline alkaloid in nature, has been shown to ex-
hibit anti-proliferation or cytotoxic effects against cancer
cells of different origins, especially in lung cancer
[19-21]. However, the mechanisms by this drug in con-
trol of NSCLC cell growth have not been well elucidated.
In this study, we confirmed that BBR inhibited NSCLC
cell proliferation and induced apoptosis. Moreover, BBR
can arrest cell cycle in G0/G1 phase in A549 cells. The
concentrations of BBR used here were consistent with or
even lower then those reported by others demonstrating
significant growth inhibition in different cell systems
[21-23]. We realized that a higher dose was needed to
inhibit different cancer cell growth, but this was within
the range of those reported by others and showed no
toxicity [21,22,24].
Induction of cell cycle arrest and apoptosis is regulated
by a large number of molecules. In our study, we found
that activation of p38αMAPK, but not ERK1/2, was medi-
ated the effect of BBR on cell cycle arrest and induction of
p53 and FOXO3a protein expression. Of notes, we dem-
onstrated the unique role of p38α isoform played in this
process, whether other p38 isoforms, such as p38γ or
p38δ MAPK were also involved in this response required
to be determined in the future studies. Consistent with
this, the role of p38 MAPK pathway in mediating thecancer cell growth inhibition and induction of apoptosis
has been established and reported [25-27]. The p38
MAPK pathway negatively regulated cell proliferation and
tumorigenesis. Inactivation of the p38 pathway enhanced
cellular transformation and rendered mice prone to tumor
development with concurrent disruption of the induction
of senescence. Conversely, persistent activation of p38
inhibited tumorigenesis, suggesting a tumor-suppressing
function of the p38 pathway [25]. Our results suggested
that activation of p38 MAPK was required in mediating
the effect of BBR on induction of tumor suppressors p53
and FOXO3a, and lung cancer cell cycle arrest. Note that
activation of ERK/12 by BBR played no role in this
process, which were different or even opposite reported
by others [28,29]. The discrepancy remained unclear; dif-
ferent cell lines and culture conditions may account for
this, which needs to be determined with more experi-
ments in the future. The cross-talk between ERK and p38
signaling pathways was reported in other studies [30,31].
However, in this study we have not observed this link.
Thus, more experiments may require to confirm this.
In this study, we demonstrated the important role of
tumor suppressor p53 in mediating the effect of BBR on
cell proliferation and cell cycle arrest, which were consist-
ent with other studies [24,32] suggesting that a p53-
dependent pathway was required in this process. Tumor
suppressor p53 plays a significant role in the regulation of
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Figure 3 Berberine increased the phosphorylation of p38 MAPK and ERK1/2 in a time-dependent manner. A-B, A549 cells were treated
with BBR (25 μM) in the indicated times, and cell lysate was harvested and the expression of the phosphorylated or total protein of ERK1/2, p38
MAPK were measured by Western blot analysis using corresponding antibodies. GAPDH was used as loading control. The bar graphs represented
the densitometry results of p-ERK (A) or p38 MAPK (B)/GAPDH as mean ± SD of at least three separate experiments. *indicates significant
difference from untreated control cells (P < 0.05).
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cers [33,34]. p53 controls both the G2/M and the G1 cell
cycle checkpoints and mediates reversible growth arrest in
human fibroblasts [35]. Increased expression of wild-type
p53 arrested cells late in the G1 stage of the cell cycle by
stimulating the synthesis of inhibitors of cyclin-dependent
kinase p21 (CIP1/WAF1) [35]. Consistent with this, we
found that BBR increased p21 protein expression in hu-
man lung cancer A549 cells, which was eliminated (not
observed) in cells silencing of p53 gene. This suggested
that BBR-induced p21 (CIP1/WAF1) was through p53-
dependent pathway. P21 (CIP1/WAF1) is a direct target
of p53 [36], thus, p53 mediated induction of p21 (CIP1/
WAF1) at least contributed to the inhibitory effect of
BBR on cell proliferation and cell cycle arrest.
On the other hand, our results suggested that activation
of p38 MAPK mediated the BBR-induced FOXO3a pro-
tein expression and the latter also contributed to the BBR-
inhibited cell growth and -induced apoptosis. It is possible
that the inhibition of proliferation can be in part a conse-
quence of increased cell apoptosis or vise versa. The
FOXO3a is an important tumor suppressor and is under-
expressed in many cancers. There are a number of paral-
lels between FOXO3a and p53, both play a pivotal role in
regulating the cellular response to stress and damage sig-
nals, inducing cell cycle arrest, apoptosis, and DNA repair[37]. Several studies showed that FOXO3a interacts with
p53, and that FOXO3a is a p53 target gene [15,38]. In this
study, we demonstrated that the potential interaction and
mutually exclusive events of p53 and FOXO3a may con-
tribute to enhance BBR-induced apoptosis and -inhibited
cell proliferation. However, the detailed mechanism
underlining the regulation of these transcriptional net-
works in mediating the effect of BBR on the control of
lung cancer cell survival needs to be elucidated.
Our results also demonstrated a causative role of
FOXO3a in mediated the effect of BBR on p21 (CIP1/
WAF1) expression. We showed that the knockdown of
FOXO3a blocked, while overexpression of FOXO3a aug-
mented the increase in p21 (CIP1/WAF1) protein ex-
pression in BBR-treated cells. These, together with the
observation from silencing of p53 experiments indicated
that p21 (CIP1/WAF1) is not only the direct target of
p53 but also function as FOXO3a downstream effector,
which may be through the p53-independent way [17].
p53 and FOXO3a share similar target genes including
p21(CIP1/WAF1), FOXO factors bind to the promoter
of p21 to induce cell cycle arrest at the G1/S transition
[39]. Given the fact that p21 (CIP1/WAF1) is involved in
regulation of fundamental cellular processes, such as cell
proliferation, differentiation, regulation of gene tran-






















































































































































































































































































































































































































Figure 4 Berberine increased p53 and FOXO3a protein expression through p38α MAPK pathway. A, A549 cells were exposed to
increased concentration of BBR for 24 h. Afterwards, the expression of FOXO3a and p53 protein were detected by Western blot. B-C, A549 cells
were treated with SB203580 (10 μM) (B), or p38α, β siRNAs (70 nM each) (C) for 2 h or 30 h before exposure of the cells to BBR (25 μM) for an
additional 24 h. Afterwards, the expression of p38 α or β isoforms, p53 and FOXO3a protein was detected by Western blot. D, A549 cells were
treated with PD98059 (20 μM) for 2 h and 30 before exposure of the cells to BBR (25 μM) for an additional 24 h. Afterwards, the expression of
p53 and FOXO3a protein was detected by Western blot. The bar graphs represent the mean ± SD of p53/GAPDH and FOXO3a/GAPDH of three
independent experiments. E-F, A549 cells were treated with SB203580 (10 μM) for 2 h before exposure of the cells to BBR (25 μM) for an
additional 24 h. Afterwards, the cells were collected and processed for analysis of cell cycle distribution by Flow cytometry after propidium
iodide (PI) staining (E). And the percentages of the cell population in each phase (G0/G1, S and G2/M) of cell cycle were assessed by Multicycle
AV DNA Analysis Software. Data are expressed as a percentage of total cells. Values are given as the mean ± SD of relative percentage of cell
cycle phases from 3 independent experiments performed in triplicate. In separated experiment, the cell viability was determined using the MTT
assay (F). *indicates significant difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from BBR
treated alone (P < 0.05).
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Figure 5 BBR-induced inhibition of cell growth and induction of apoptosis were dependent on p53 and FOXO3a protein expression in
A549 cells. A-B, A549 cells were treated with Pifithrin-α (10 μM) for 2 h before exposure the cells to BBR (25 μM) for an additional 24 h followed
by measuring the p53 protein expression (A). GAPDH was used as internal control (A). And cell cycle was analyzed by flow cytometry after
propidium iodide (PI) staining (B). The bar graphs represent the mean ± SD of p53/GAPDH or relative percentage of cell cycle phases of three
independent experiments. C-D, Cells were transfected with control or p53 or FOXO3a siRNAs with lipofectamine 2000 reagent for 24 h, followed
by exposure the cells to BBR (25 μM) for an additional 24 h. Afterwards, the cell proliferation was detected using MTT assays. The expression of
p53 and FOXO3a protein was determined by Western blot. The bar graphs represent the mean ± SD of p53/GAPDH and FOXO3a/GAPDH of three
independent experiments. E, Cells were transfected with control or FOXO3a siRNAs (50 nM each) for 24 h before exposing the cell to BBR for an
additional 24 h. Afterwards, cell apoptosis was determined by flow cytometry assays. F, Cells were transfected with control (pEGFP-N1) or FOXO3a
expression vector (FOXO3a-pEGFP) for 24 h before exposing the cells to BBR for an additional 24 h. Afterwards, the expression of FOXO3a protein
and apoptosis were detected by Western blot and flow cytometry, respectively. Data are expressed as a percentage of total cells. Values in bar
graphs were given as the mean ± SD from three independent experiments performed in triplicate. *indicates significant difference as compared
to the untreated control group (P < 0.05). **Indicates significant difference from BBR treated alone (P < 0.05).
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Figure 6 Berberine increased p21 protein expression through induction of FOXO3a and p53 protein expressions. A-B, A549 cells were
exposed to increased concentration of BBR for 24 h, followed by measuring the protein expression of p21 and cyclin D1 by Western blot. The bar
graphs represent the mean ± SD of p21/β-actin or cyclinD1/β-actin of three independent experiments. C-D, A549 cells were transfected with
control or p53 or FOXO3a siRNAs (50 nM each) for 24 h prior to exposure of the cells to 25 μM BBR for an additional 24 h. Afterwards, Western
blot analysis were used measure the protein levels of p53, FOXO3a and p21 using corresponding antibodies. E, Cells were transfected with
control (pEGFP-N1) or FOXO3a expression vector (FOXO3a-pEGFP) for 24 h before exposing the cells to BBR for an additional 24 h. Afterwards,
the expression of p21 protein was detected by Western blot. The bar graphs represent the mean ± SD of p21/β-actin of three independent
experiments. *indicates significant difference from control (P < 0.05).
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http://www.jeccr.com/content/33/1/36expression may contribute to induce cell apoptosis,
which could be in part a consequence of inhibition of
NSCLC cell growth. Of note, the dual function of p21
(Cip1/Waf1) was observed in cancerogenesis. On the
one hand, p21 (Cip1/Waf1) acts as a tumor suppressor;
on the other hand, it prevents apoptosis and acts as an
oncogene [40,42]. Therefore, precise understanding the
role of p21 (Cip1/Waf1) and relevant signaling pathwaysinvolved would help to develop better cancer-treatment
strategies.
Study showed that activation of p38 MAPK reduced
protein expression of cyclin D1, another cell cycle regu-
lator [43]. Cyclin D1 actives cyclin dependent kinase 4
and 6 (Cdk4/6) and this active complex is essential for
the transition to S-phase and further stimulates cell pro-
liferation [44]. In our study, we showed that BBR
Zheng et al. Journal of Experimental & Clinical Cancer Research 2014, 33:36 Page 11 of 12
http://www.jeccr.com/content/33/1/36decreased the cyclin D1 protein expression, but this was
not through the p53- or FOXO3a-dependent pathway,
which consistent with other studies [45] although oppos-
ite results were observed [12,46]. Thus, more studies are
required to elucidate the truly connections and precise
mechanism underlining this. In addition, whether the
BBR-induced pro-apoptotic signaling by p38 MAPK is
also activated and the functions of FOXO3a are regulated
by p38 MAPK in cells silencing of p53 need to be deter-
mined. This may further elucidate pleiotropic anti-cancer
mechanisms of this medicinal phyto-chemical compound.
Conclusion
In summary, our data demonstrate that BBR inhibits growth
and induces cell cycle arrest in G0/G1 phase, and apoptosis
in NSCLC cells through p38αMAPK-mediated induction of
p53 and FOXO3a, followed by p21 protein expression.
Thus, the parallel induction and mutually exclusive inter-
action of p53 and FOXO3a, which act in concert, contribute
to mediate the overall responses of NSCLC cell to BBR.
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